EDGAR Filing Documents for 0001104659-20-101436

Form S-3 - Registration statement under Securities Act of 1933:

SEC Accession No. 0001104659-20-101436

Filing Date

2020-09-01

Accepted

2020-09-01 16:50:38

Documents

Document Format Files

Seq	Description	Document	Type	Size
1	S-3	tm2029923-1_s3.htm	S-3	569165
2	EXHIBIT 4.2	tm2029923d2_ex4-2.htm	EX-4.2	357362
3	EXHIBIT 4.3	tm2029923d2_ex4-3.htm	EX-4.3	388894
4	EXHIBIT 4.4	tm2029923d2_ex4-4.htm	EX-4.4	43418
5	EXHIBIT 4.5	tm2029923d2_ex4-5.htm	EX-4.5	44175
6	EXHIBIT 5.1	tm2029923d2_ex5-1.htm	EX-5.1	30142
7	EXHIBIT 23.1	tm2029923d2_ex23-1.htm	EX-23.1	3234
8	GRAPHIC	tm2029923d2_ex5-1img001.jpg	GRAPHIC	4190
9	GRAPHIC	lg_nabriva-4c.jpg	GRAPHIC	523958
	Complete submission text file	0001104659-20-101436.txt		2128710

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406

Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640

Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)